GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » EV-to-Revenue

Guizhounli Pharmaceutical Co (SHSE:603439) EV-to-Revenue : 3.58 (As of May. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Guizhounli Pharmaceutical Co's enterprise value is ¥6,119 Mil. Guizhounli Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,708 Mil. Therefore, Guizhounli Pharmaceutical Co's EV-to-Revenue for today is 3.58.

The historical rank and industry rank for Guizhounli Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SHSE:603439' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.13   Med: 5.25   Max: 20.17
Current: 3.66

During the past 11 years, the highest EV-to-Revenue of Guizhounli Pharmaceutical Co was 20.17. The lowest was 0.13. And the median was 5.25.

SHSE:603439's EV-to-Revenue is ranked better than
69.08% of 1038 companies
in the Biotechnology industry
Industry Median: 8.145 vs SHSE:603439: 3.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Guizhounli Pharmaceutical Co's stock price is ¥15.42. Guizhounli Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4.15. Therefore, Guizhounli Pharmaceutical Co's PS Ratio for today is 3.71.


Guizhounli Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co EV-to-Revenue Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 12.70 6.43 4.34 4.84

Guizhounli Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.98 4.80 4.78 4.84 3.95

Competitive Comparison of Guizhounli Pharmaceutical Co's EV-to-Revenue

For the Biotechnology subindustry, Guizhounli Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guizhounli Pharmaceutical Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guizhounli Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Guizhounli Pharmaceutical Co's EV-to-Revenue falls into.



Guizhounli Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Guizhounli Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6118.824/1708.024
=3.58

Guizhounli Pharmaceutical Co's current Enterprise Value is ¥6,119 Mil.
Guizhounli Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,708 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhounli Pharmaceutical Co  (SHSE:603439) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Guizhounli Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.42/4.151
=3.71

Guizhounli Pharmaceutical Co's share price for today is ¥15.42.
Guizhounli Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhounli Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhounli Pharmaceutical Co (SHSE:603439) Business Description

Traded in Other Exchanges
N/A
Address
Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Executives
Zhang Hong Yu Directors, senior managers
Wang Yi senior management
Zhang Qian Fan Directors, senior managers
Sheng Yong Jian Director

Guizhounli Pharmaceutical Co (SHSE:603439) Headlines

No Headlines